Navidea Biopharmaceuticals (NAVB) 10-Q 15 Aug 22 2022 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 08, 2022
Document Information [Line Items]
Entity Central Index Key	0000810509
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-35076
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-1080091
Entity Address, Address Line One	4995 Bradenton Avenue, Suite 240
Entity Address, City or Town	Dublin
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	43017-3552
City Area Code	614
Local Phone Number	793-7500
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		30,367,292
Preferred Stock Purchase Rights [Member]
Document Information [Line Items]
Title of 12(b) Security	Preferred Stock Purchase Rights
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	NAVB
Security Exchange Name	NYSEAMER

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 328,012	$ 4,230,865
Receivables	30,069	92,992
Inventory, net	315,670	151,155
Prepaid expenses and other	496,989	908,273
Total current assets	1,170,740	5,383,285
Property and equipment	821,416	866,306
Less accumulated depreciation and amortization	673,493	745,816
Property and equipment, net	147,923	120,490
Right-of-use lease assets	448,940	448,940
Less accumulated amortization	381,654	320,725
Right-of-use lease assets, net	67,286	128,215
License agreements, patents and trademarks	1,081,762	953,424
Less accumulated amortization	191,198	167,773
License agreements, patents and trademarks, net	890,564	785,651
Other assets	227,192	227,192
Total assets	2,503,705	6,644,833
Current liabilities:
Accounts payable	2,426,652	1,421,317
Accrued liabilities and other	2,776,924	3,149,340
Note payable, current	0	453,427
Lease liabilities, current	118,409	275,718
Total current liabilities	5,321,985	5,299,802
Lease liabilities, net of current portion	2,062	20,288
Deferred revenue	700,000	700,000
Note payable to related party, net of discount of $779,695	720,305	0
Total liabilities	6,744,352	6,020,090
Commitments and contingencies (See Note 10)
Stockholders’ (deficit) equity:
Common stock; $.001 par value, 300,000,000 shares authorized; 30,364,792 and 30,279,922 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	221,361	221,277
Additional paid-in capital	372,019,758	370,459,705
Accumulated deficit	(376,774,310)	(370,787,610)
Total stockholders' deficit	(4,533,164)	(106,556)
Noncontrolling interest	292,517	731,299
Total Navidea stockholders’ (deficit) equity	(4,240,647)	624,743
Total liabilities and stockholders’ (deficit) equity	2,503,705	6,644,833
Non-Series Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	0	0
Series D Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	22	22
Series E Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	0	50
Series F Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	2	0
Series G Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	3	0
Series H Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	30,364,792	30,279,922
Common stock, shares outstanding (in shares)	30,364,792	30,279,922
Non-Series Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series D Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	150,000	150,000
Preferred stock, shares issued (in shares)	22,077	22,077
Preferred stock, shares outstanding (in shares)	22,077	22,077
Series E Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	50,000	50,000
Preferred stock, shares issued (in shares)	0	50,000
Preferred stock, shares outstanding (in shares)	0	50,000
Series F Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,740	1,740
Preferred stock, shares issued (in shares)	1,740	0
Preferred stock, shares outstanding (in shares)	1,740	0
Series G Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	3,260	3,260
Preferred stock, shares issued (in shares)	3,260	0
Preferred stock, shares outstanding (in shares)	3,260	0
Series H Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	75,000	75,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Note Payable to Related Party [Member]
Note payable to related party, discount	$ 779,695

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Sales revenue		$ 6,519	$ 13,063	$ 6,519	$ 35,549
Revenue		6,519	13,063	6,519	35,549
Grant and other revenue		51,007	247,983	51,007	349,234
Total revenue		57,526	261,046	57,526	384,783
Cost of revenue		473	0	473	0
Gross profit		57,053	261,046	57,053	384,783
Operating expenses:
Research and development		1,723,988	1,498,056	2,893,242	2,720,810
Selling, general and administrative		1,255,666	1,432,610	3,065,695	3,663,355
Total operating expenses		2,979,654	2,930,666	5,958,937	6,384,165
Loss from operations	[1]	(2,922,601)	(2,669,620)	(5,901,884)	(5,999,382)
Other (expense) income:
Interest (expense) income, net		(83,584)	1,266	(87,246)	(1,609)
Gain on extinguishment of debt		0	0	0	366,000
Other, net		6,726	(5,686)	2,427	(5,941)
Total other (expense) income, net		(76,858)	(4,420)	(84,819)	358,450
Net loss		(2,999,459)	(2,674,040)	(5,986,703)	(5,640,932)
Loss attributable to noncontrolling interest		1	1	3	3
Net loss attributable to common stockholders		$ (2,999,458)	$ (2,674,039)	$ (5,986,700)	$ (5,640,929)
Loss attributable to common stockholders per common share (basic and diluted) (in dollars per share)		$ (0.10)	$ (0.09)	$ (0.20)	$ (0.20)
Weighted average shares outstanding (in shares)		30,268,858	29,117,832	30,238,471	28,531,660
Sales Revenue [Member]
Revenue:
Sales revenue		$ 6,519	$ 0	$ 6,519	$ 0
Revenue		6,519	0	6,519	0
License [Member]
Revenue:
Sales revenue		0	13,063	0	35,549
Revenue		$ 0	$ 13,063	$ 0	$ 35,549
[1]Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($)	Preferred Stock [Member] Director Fees [Member]	Preferred Stock [Member] Series D Preferred Stock [Member]	Preferred Stock [Member] Series E Preferred Stock [Member]	Preferred Stock [Member]	Preferred Stock Subscription [Member] Series D Preferred Stock [Member]	Preferred Stock Subscription [Member] Series E Preferred Stock [Member]	Preferred Stock Subscription [Member]	Preferred Stock Subscriptions Receivable [Member] Series D Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member] Series E Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member]	Common Stock [Member] Director Fees [Member]	Common Stock [Member] Series D Preferred Stock [Member]	Common Stock [Member] Series E Preferred Stock [Member]	Common Stock [Member]	Common Stock Subscription [Member] Series D Preferred Stock [Member]	Common Stock Subscription [Member] Series E Preferred Stock [Member]	Common Stock Subscription [Member]	Common Stock Subscriptions Receivable [Member] Series D Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member] Series E Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member]	Additional Paid-in Capital [Member] Director Fees [Member]	Additional Paid-in Capital [Member] Series D Preferred Stock [Member]	Additional Paid-in Capital [Member] Series E Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Director Fees [Member]	Retained Earnings [Member] Series D Preferred Stock [Member]	Retained Earnings [Member] Series E Preferred Stock [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member] Director Fees [Member]	Noncontrolling Interest [Member] Series D Preferred Stock [Member]	Noncontrolling Interest [Member] Series E Preferred Stock [Member]	Noncontrolling Interest [Member]	Director Fees [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2020				0			132,250							27,149,691			995,000
Balance at Dec. 31, 2020				$ 0			$ 132			$ (10,300,000)				$ 218,146			$ 995			$ (4,975,000)				$ 375,428,014				$ (359,056,683)				$ 731,303				$ 2,046,907
Issued stock to 401(k) plan (in shares)				0			0							30,018			0
Issued stock to 401(k) plan				$ 0			$ 0			0				$ 30			$ 0			0				76,816				0				0				76,846
Stock compensation expense				0			0			0				0			0			0				121,298				0				0				121,298
Net loss				$ 0			0			0				0			0			0				0				(2,966,890)				(2)				(2,966,892)
Issued Stock (in shares)		31,750	50,000		(31,750)	0						0	0		0	0
Issued Stock		$ 32	$ 50		$ (31)		$ 0	$ 250,000	$ 0					$ 0			$ 0	$ 0	$ 0			$ 0	$ 4,980,659			$ 0	$ 0			$ 0	$ 0			$ 250,001	$ 4,980,709
Issued restricted stock (in shares)				0			0							12,500			0
Issued restricted stock				$ 0			$ 0			0				$ 13			$ 0			0				0				0				0				13
Issued stock (in shares)		31,750	50,000		(31,750)	0						0	0		0	0
Issued stock		$ 32	$ 50		$ (31)		0	250,000	$ 0					$ 0			0	0	$ 0			0	$ 4,980,659			0	$ 0			0	$ 0			250,001	$ 4,980,709
Issued stock upon conversion (in shares)		(31,750)			0							1,513,978			0
Issued stock upon conversion		$ (32)					$ 0	0				$ 1,514					$ 0	0				(1,482)				0				0				0
Stock subscribed (in shares)		0			0							0			0
Stock subscribed		$ 0			$ 0			500,000				$ 0			$ 0			0				0				0				0				500,000
Stock subscribed (in shares)		0			0							0			0
Balance (in shares) at Mar. 31, 2021				50,000			100,500							28,706,187			995,000
Balance at Mar. 31, 2021				$ 50			$ 101			(9,550,000)				$ 219,703			$ 995			(4,975,000)				380,605,305				(362,023,573)				731,301				5,008,882
Balance (in shares) at Dec. 31, 2020				0			132,250							27,149,691			995,000
Balance at Dec. 31, 2020				$ 0			$ 132			(10,300,000)				$ 218,146			$ 995			(4,975,000)				375,428,014				(359,056,683)				731,303				$ 2,046,907
Issued stock to 401(k) plan (in shares)																																				30,018
Issued stock to 401(k) plan																																				$ 76,846
Net loss																																				(5,640,932)
Balance (in shares) at Jun. 30, 2021				50,000			22,077							30,145,718			0
Balance at Jun. 30, 2021				$ 50			$ 22			0				$ 221,142			$ 0			0				370,181,268				(364,697,612)				731,300				6,436,170
Balance (in shares) at Mar. 31, 2021				50,000			100,500							28,706,187			995,000
Balance at Mar. 31, 2021				$ 50			$ 101			(9,550,000)				$ 219,703			$ 995			(4,975,000)				380,605,305				(362,023,573)				731,301				5,008,882
Stock compensation expense				0			0			0				0			0			0				142,180				0				0				142,180
Net loss				$ 0			$ 0			0				$ 0			$ 0			0				0				(2,764,039)				(1)				(2,674,040)
Issued Stock (in shares)				23,000			(23,000)							0			0
Issued Stock				$ 23			$ (23)			1,800,000				$ 0			$ 0			0				0				0				0				1,800,000
Issued stock (in shares)				23,000			(23,000)							0			0
Issued stock				$ 23			$ (23)			1,800,000				$ 0			$ 0			0				0				0				0				1,800,000
Issued stock upon conversion (in shares)				(23,000)			0							1,437,531			0
Issued stock upon conversion				$ (23)			$ 0			0				$ 1,437			$ 0			0				(1,414)				0				0				0
Stock subscribed (in shares)		0		0	55,423		0					0		0	0		(995,000)
Stock subscribed		$ 0		$ 0	$ (56)		$ 0	$ 7,750,000		0		$ 0		$ 0	$ 0		$ (995)	$ 0		4,975,000		$ (5,542,245)		(4,974,005)		$ 0		0		$ 0		0		$ 2,207,699		0
Stock subscribed (in shares)		0		0	(55,423)		0					0		0	0		995,000
Incurred costs related to Series E Preferred Stock				$ 0			$ 0			0				$ 0			$ 0			0				(50,671)				0				0				(50,671)
Issued stock upon stock option exercise (in shares)				0			0							2,000			0
Issued stock upon stock option exercise				$ 0			$ 0			0				$ 2			$ 0			0				2,118				0				0				2,120
Balance (in shares) at Jun. 30, 2021				50,000			22,077							30,145,718			0
Balance at Jun. 30, 2021				$ 50			$ 22			$ 0				$ 221,142			$ 0			$ 0				370,181,268				(364,697,612)				731,300				6,436,170
Balance (in shares) at Dec. 31, 2021				72,077										30,279,922
Balance at Dec. 31, 2021				$ 72										$ 221,277										370,459,705				(370,787,610)				731,299				624,743
Issued stock in lieu of cash bonuses (in shares)				0										16,632
Issued stock in lieu of cash bonuses				$ 0										$ 17										16,948				0				0				16,965
Issued stock to 401(k) plan (in shares)				0										53,238
Issued stock to 401(k) plan				$ 0										$ 53										44,667				0				0				44,720
Issued stock in lieu of cash for payment of director fees (in shares)	0										7,500
Issued stock in lieu of cash for payment of director fees	$ 0										$ 7										$ 6,518				$ 0				$ 0				$ 6,525
MT Preferred Stock reacquired due to Platinum settlement				0										0										438,778				0				(438,778)				0
Stock compensation expense				0										0										184,850				0				0				184,850
Net loss				$ 0										$ 0										0				(2,987,242)				(3)				(2,987,245)
Balance (in shares) at Mar. 31, 2022				72,077										30,357,292
Balance at Mar. 31, 2022				$ 72										$ 221,354										371,151,466				(373,774,852)				292,518				(2,109,442)
Balance (in shares) at Dec. 31, 2021				72,077										30,279,922
Balance at Dec. 31, 2021				$ 72										$ 221,277										370,459,705				(370,787,610)				731,299				$ 624,743
Issued stock to 401(k) plan (in shares)																																				53,238
Issued stock to 401(k) plan																																				$ 44,720
Net loss																																				(5,986,703)
Balance (in shares) at Jun. 30, 2022				27,077										30,364,792
Balance at Jun. 30, 2022				$ 27										$ 221,361										372,019,758				(376,774,310)				292,517				(4,240,647)
Balance (in shares) at Mar. 31, 2022				72,077										30,357,292
Balance at Mar. 31, 2022				$ 72										$ 221,354										371,151,466				(373,774,852)				292,518				(2,109,442)
Stock compensation expense				0										0										40,554				0				0				40,554
Net loss				$ 0										$ 0										0				(2,999,458)				(1)				(2,999,459)
Series E Preferred Stock exchanged for Series F and Series G Preferred Stock (in shares)				(45,000)										0
Series E Preferred Stock exchanged for Series F and Series G Preferred Stock				$ (45)										$ 0										821,295				0				0				821,250
Issued Stock (in shares)				0										7,500
Issued Stock				$ 0										$ 7										6,443				0				0				6,450
Issued stock (in shares)				0										7,500
Issued stock				$ 0										$ 7										6,443				0				0				6,450
Balance (in shares) at Jun. 30, 2022				27,077										30,364,792
Balance at Jun. 30, 2022				$ 27										$ 221,361										$ 372,019,758				$ (376,774,310)				$ 292,517				$ (4,240,647)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (5,986,703)	$ (5,640,932)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	44,649	37,606
Amortization of debt discount and issuance costs	56,182	0
Non-cash lease expense	60,929	60,957
Loss on abandonment of patent applications	62,388	0
Stock compensation expense	225,404	263,478
Gain on extinguishment of debt	0	(366,000)
Value of stock issued to 401(k) plan for employer matching contributions	44,720	76,846
Value of stock issued in payment of employee bonuses	16,965	0
Value of stock issued in payment of director fees	12,975	0
Changes in operating assets and liabilities:
Receivables	62,924	(130,218)
Inventory	(164,515)	(9,032)
Prepaid expenses and other assets	411,284	350,477
Accounts payable	1,005,335	(81,647)
Accrued and other liabilities	(418,347)	71,825
Lease liabilities	(175,535)	(156,634)
Deferred revenue	45,929	45,928
Net cash used in operating activities	(4,695,415)	(5,477,346)
Cash flows from investing activities:
Payments for purchases of equipment	(48,657)	(2,707)
Patent and trademark costs	(190,727)	(104,067)
Net cash used in investing activities	(239,384)	(106,774)
Cash flows from financing activities:
Proceeds from issuance of preferred stock, including stock subscriptions receivable	0	10,475,000
Proceeds from issuance of common stock	0	2,133
Proceeds from note payable	1,500,000	0
Payment of debt issuance costs	(14,627)	0
Principal payments on notes payable	(453,427)	(379,443)
Net cash provided by financing activities	1,031,946	10,027,728
Net (decrease) increase in cash and cash equivalents	(3,902,853)	4,443,608
Cash and cash equivalents, beginning of period	4,230,865	2,670,495
Cash and cash equivalents, end of period	328,012	7,114,103
Preferred Stock Issuance Costs [Member]
Cash flows from financing activities:
Payment of stock issuance costs	$ 0	$ (69,962)

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Summary of Significant Accounting Policies a. Basis of Presentation: June 30, 2022 three six June 30, 2022 2021 June 30, 2022 not December 31, 2021, 10 March 28, 2022 ( “2021 10 Our condensed consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Europe Limited (“Navidea Europe”) and Navidea Biopharmaceuticals Limited (“Navidea UK”), as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. b. Revenue Recognition: one We also earn revenue from product sales to end customers, primarily in Europe. Revenue from product sales is generally recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Our customers have no may In addition, we earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development (“R&D”) costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. c Research and Development Costs: d. Inventory: first first 6. e. Intangible Assets: no six June 30, 2022 2021, six June 30, 2022 2021, f. Leases: 2018. 12 not 9. g. Contingent Liabilities: 450, Contingencies 10 10. h. Recently Adopted Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 2021 04 2021 04 December 15, 2021, 2021 04 not In November 2021, No. 2021 10, Disclosures by Business Entities about Government Assistance 2021 10 2021 10 1 2 3 2021 10 December 15, 2021. 2021 10 1 2 2021 10 not

Note 2 - Liquidity

Note 2 - Liquidity	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity As disclosed in the notes to the consolidated financial statements included in the Company’s 2021 10 10. On April 10, 2022, July 1, 2022. two second first 8 16. Beginning August 4, 2022 August 17, 2022, August 3, 2022 one may 3 We do not 19 19 NAV3 32 19 19 The current conflict between Ukraine and Russia has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may third may The Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The Company also continues working to establish new sources of funding, including the Rights Offering that is currently underway, other potential equity investments, collaborations and additional grant funding that can augment the balance sheet. However, based on our current working capital and our projected cash burn, management believes that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one 10

Note 3 - Revenue From Contracts

Note 3 - Revenue From Contracts With Customers	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenue from Contracts with Customers Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 We earn revenue from product sales to end customers, primarily in Europe. Revenue from product sales is generally recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Our customers have no may 30 90 The Company also recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 to 90 days following milestone achievement or royalty invoice, in accordance with each contract. Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m Tc99m March 2022, not Tc99m not no not eight ten The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. Tc99m not no no Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not During the three June 30, 2022 2021, six June 30, 2022 2021, three six June 30, 2022 2021, not The following table disaggregates the Company’s revenue from contracts with customers for the three six June 30, 2022 2021. Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Sales revenue: Tc99m tilmanocept - Europe $ 6,519 $ — $ 6,519 $ — License revenue: Tc99m tilmanocept - Europe $ — $ 13,063 $ — $ 35,549 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m March 2022, not Tc99m not may NAV4694 not Through June 30, 2022, not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the condensed consolidated balance sheets, during the three six June 30, 2022 2021. Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Total deferred revenue, beginning of period $ 800,000 $ 700,000 $ 700,000 $ 700,000 Deferred revenue related to milestones achieved — — 100,000 — Deferred revenue related to milestones achieved, written off due to contract renegotiations (100,000 ) — (100,000 ) — Total deferred revenue, end of period $ 700,000 $ 700,000 $ 700,000 $ 700,000 The Company had sales revenue receivable of $3,903 and $0 outstanding as of June 30, 2022 December 31, 2021, June 30, 2022 December 31, 2021, In addition to revenue from contracts from customers, we also generate revenue from National Institutes of Health (“NIH”) grants to support various product development initiatives. The revenue recognition standard applies to revenue from contracts with customers. A customer is defined as a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ongoing major or central operations in exchange for consideration. The Company’s ongoing major or central operations consist of the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The NIH and its various institutes are responsible for biomedical and public health research and provide major biomedical research funding to non-NIH research facilities and entities such as Navidea. While the Company will directly benefit from any knowledge gained from the project, there is also a public health benefit provided, which justifies the use of public funds in the form of the grants. Based on the nature of the Company’s operations and the terms of the grant awards, Navidea does not not three June 30, 2022 2021, six June 30, 2022 2021,

Note 4 - Stock-based Compensati

Note 4 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	4. Stock-Based Compensation For the three June 30, 2022 2021, six June 30, 2022 2021, not three six June 30, 2022 2021. A summary of the status of our stock options as of June 30, 2022, six Six Months Ended June 30, 2022 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding, January 1, 2022 919,790 $ 5.67 6.5 $ — Granted 12,500 0.83 Cancelled/Forfeited (152,455 ) 2.38 Expired (53,755 ) 29.32 Outstanding, June 30, 2022 726,080 $ 4.52 6.0 $ — Exercisable, June 30, 2022 545,665 $ 5.52 4.9 $ — The weighted average grant date fair value per stock option granted during the six June 30, 2022 six June 30, 2022 A summary of the status of our unvested restricted stock as of June 30, 2022, six Six Months Ended June 30, 2022 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2022 95,000 $ 1.40 Vested (5,000 ) 1.96 Unvested, June 30, 2022 90,000 $ 1.37 As of June 30, 2022,

Note 5 - Loss Per Share

Note 5 - Loss Per Share	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	5. Loss Per Share Basic loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares. Diluted loss per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may Diluted loss per common share for the six June 30, 2022 2021 The Company’s unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested restricted stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 90,000 and 60,000 shares of unvested restricted stock for the six June 30, 2022 2021,

Note 6 - Inventory

Note 6 - Inventory	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	6. Inventory, Net The components of inventory, net as of June 30, 2022 December 31, 2021 June 30, 2022 December 31, Materials $ 193,806 $ 50,000 Finished goods 123,066 101,155 Reserve for obsolete finished goods (1,202 ) — Total inventory, net $ 315,670 $ 151,155 During the three six June 30, 2021, No three six June 30, 2022.

Note 7 - Accounts Payable, Accr

Note 7 - Accounts Payable, Accrued Liabilities and Other	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	7. Accounts Payable, Accrued Liabilities and Other Accounts payable as of June 30, 2022 December 31, 2021 June 30, 2022 December 31, 2021 June 30, 2022 December 31, 2021.

Note 8 - Notes Payable

Note 8 - Notes Payable	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Notes Payable Bridge Note from John K. Scott, Jr. On April 10, 2022, July 1, 2022. two second first 11 16. As consideration and partial inducement for Mr. Scott to enter into the Bridge Note, the Company exchanged all 50,000 shares of Mr. Scott’s Series E Redeemable Convertible Preferred Stock (“Series E Preferred Stock”) for 1,740 shares of Series F Preferred Stock and 3,260 shares of Series G Preferred Stock. In accordance with current accounting guidance, the Company recorded a debt discount of $835,876 including $821,250 related to the difference in the value of Mr. Scott’s Series E Preferred Stock and the Series F and Series G Preferred Stock and $14,626 of debt issuance costs. The debt discount is being amortized as non-cash interest expense using the effective interest method over the term of the Bridge Note. The balance of the debt discount was $779,695 as of June 30, 2022. Interest expense related to the Bridge Note totaled $83,182 during the three six June 30, 2022. June 30, 2022. IPFS Corporation In November 2020, seven June 2021. November 2021, five April 2022. Interest expense related to the IPFS notes payable totaled $414 and $1,113 during the three June 30, 2022 2021, six June 30, 2022 2021, June 30, 2022. Summary During the three June 30, 2022 2021, six June 30, 2022 2021,

Note 9 - Leases

Note 9 - Leases	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. Leases We currently lease approximately 5,000 square feet of office space at 4995 June 2023. In addition, we currently lease approximately 25,000 square feet of office space at 5600 2022. October 2022 five not June 2017, October 2022. We currently lease office equipment at a monthly payment of $136, expiring in October 2024. September 2021. Total operating lease expense was $35,497 and $43,913 for the three June 30, 2022 2021, six June 30, 2022 2021, The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of June 30, 2022. Maturity of Lease Liabilities Operating Lease 2022 (remaining) $ 103,332 2023 19,699 2024 1,355 Total undiscounted operating lease payments 124,386 Less imputed interest 3,915 Present value of operating lease liabilities $ 120,471 Balance Sheet Classification Current lease liabilities $ 118,409 Noncurrent lease liabilities 2,062 Total operating lease liabilities $ 120,471 Other Information Weighted-average remaining lease term for operating leases (in years) 0.6 Weighted-average discount rate for operating leases 10.9 % Cash paid for amounts included in the present value of operating lease liabilities was $187,779 and $185,421 during the six June 30, 2022 2021,

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. In accordance with ASC Topic 450, Contingencies not CRG Litigation As disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10 April 2018, not On November 21, 2021, not August 26, 2022. not The Company had also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio (the “Ohio Court”) related to Navidea’s claims that the CRG Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the CRG Lenders in connection with the GSA, pursuant to which Navidea agreed to pay up to $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 7, 2019, June 28, 2019. November 27, 2019, $66.0 April 9, 2018, 414 no December 5, 2019, 10th March 27, 2020, September 23, 2020. March 16, 2021, 10th November 27, 2019 not not Platinum Litigation In November 2017, March 3, 2017, October 31, 2018, no On November 30, 2018, January 22, 2019, September 5, 2019. November 25, 2019, not June 4, 2020, September 2, 2020, September 23, 2020 June 28, 2021. January 2022, 11. Goldberg Agreement and Litigation In August 2018, 1,175,000 November 2018, On February 11, 2019, February 19, 2019, March 1, 2019, February 20, 2019, may February 17, 2022, New York Litigation Involving Dr. Goldberg On February 20, 2019, April 26, 2019, June 13, 2019, third On December 26, 2019, third not The District Court also rejected Dr. Goldberg’s claim for wrongful termination as Chief Executive Officer of MT. In addition, the District Court found that Dr. Goldberg lacked standing to seek injunctive relief to force the removal of Dr. Claudine Bruck and Michael Rice from MT’s Board of Directors, to invalidate all actions taken by the MT Board on or after November 29, 2018 ( In addition, the District Court found Navidea’s breach of fiduciary duty claim against Dr. Goldberg for conduct occurring more than three On January 31, 2020, April 1, 2020, On January 27, 2020, July 9, 2020, 1 2 3 4 On August 24, 2020, not third not On May 27, 2021, 1 2 3 not 4 not third 5 6 not On August 6, 2021, June 23, 2021 ( October 14, 2021, March 7, 2022, September 1, 2020. April 8, 2022, September 1, 2020 March 31, 2022. May 19, 2022. Fact discovery and expert discovery in the New York Action have been completed. The Company has moved to disqualify Dr. Goldberg’s damages expert and briefing in the District Court was submitted on April 1, 2022. not Delaware Litigation Involving Dr. Goldberg On February 20, 2019, June 12, 2019, not May 23, 2019 On June 23, 2021, not not December 9, 2021, NYSE American Continued Listing Standards On January 28, 2022, not $6.0 1003 February 28, 2022 July 28, 2023. On April 8, 2022, not 1003 1003 $2.0 two three $4.0 three four December 31, 2021 five December 31, 2021. The NYSE American has granted the Company a plan period through July 28, 2023 1003 not not may

Note 11 - Equity

Note 11 - Equity	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Equity Platinum Settlement As discussed in Note 10, January 2022. six Series E Preferred Stock On January 31, 2022, March 2, 2021, six NOL Rights Agreement On April 7, 2022, 382 December 31, 2021, Under the NOL Rights Agreement, the Board declared a non-taxable dividend of one one one may five not The rights issued under the NOL Rights Agreement will expire on the earliest of (i) April 6, 2025; ( 382 no first no may 2022 not Stock Exchange and Loan Agreement On April 10, 2022, two second first As consideration and a partial inducement for Mr. Scott to make the loan, at the closing, Mr. Scott delivered 50,000 shares of Series E Preferred Stock, representing 100% may may not 33.33% 33.33% April 12, 2022. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with Mr. Scott, pursuant to which the Company agreed to file a registration statement with the SEC to register the resale of the shares issuable to Mr. Scott upon conversion of the Series F Preferred Stock. 401 During the six June 30, 2022 2021, 401 Bonuses Paid in Stock During the six June 30, 2022, 2021

Note 12 - Stock Warrants

Note 12 - Stock Warrants	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	12. Stock Warrants On March 3, 2022, As of June 30, 2022,

Note 13 - Income Taxes

Note 13 - Income Taxes	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes Income taxes are accounted for under the asset and liability method in accordance with Accounting Standards Codification 740, Income Taxes Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not June 30, 2022 December 31, 2021. In assessing the realizability of DTAs, management considers whether it is more likely than not not not not June 30, 2022. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no liability for uncertain tax positions was recorded as of June 30, 2022 December 31, 2021 not twelve June 30, 2022, 2018 2021 As of June 30, 2022, 2022 2037.

Note 14 - Segments

Note 14 - Segments	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	14. Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no inter-segment sales. We manage our business based on two Tc99m The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended June 30, 2022 Diagnostics Therapeutics Corporate Total Sales revenue: United States $ — $ — $ — $ — International 6,519 — — 6,519 Grant and other revenue 51,007 — — 51,007 Total revenue 57,526 — — 57,526 Cost of revenue, excluding depreciation and amortization 473 — — 473 Research and development expenses 1,636,691 87,297 — 1,723,988 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,001 1,230,894 1,233,895 Depreciation and amortization (2) 6,041 — 15,730 21,771 Loss from operations (3) (1,585,679 ) (90,298 ) (1,246,624 ) (2,922,601 ) Other expense (4) — — (76,858 ) (76,858 ) Net loss (1,585,679 ) (90,298 ) (1,323,482 ) (2,999,459 ) Total assets, net of depreciation and amortization: United States $ 50,000 $ — $ 2,043,815 $ 2,093,815 International 384,294 — 25,596 409,890 Capital expenditures 40,221 — 8,436 48,657 Three Months Ended June 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 13,063 $ — $ — $ 13,063 Grant and other revenue 247,983 — — 247,983 Total revenue 261,046 — — 261,046 Research and development expenses 1,358,123 139,933 — 1,498,056 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 873 1,411,879 1,412,752 Depreciation and amortization (2) 6,041 — 13,817 19,858 Loss from operations (3) (1,103,118 ) (140,806 ) (1,425,696 ) (2,669,620 ) Other expense (4) — — (4,420 ) (4,420 ) Net loss (1,103,118 ) (140,806 ) (1,430,116 ) (2,674,040 ) Total assets, net of depreciation and amortization: United States $ 269,464 $ — $ 10,811,515 $ 11,080,979 International 199,741 — 590 200,331 Capital expenditures — — 2,707 2,707 Six Months Ended June 30, 2022 Diagnostics Therapeutics Corporate Total Sales revenue: United States $ — $ — $ — $ — International 6,519 — — 6,519 Grant and other revenue 51,007 — — 51,007 Total revenue 57,526 — — 57,526 Cost of revenue, excluding depreciation and amortization 473 — — 473 Research and development expenses 2,626,578 266,664 — 2,893,242 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,001 3,018,045 3,021,046 Depreciation and amortization (2) 12,081 — 32,568 44,649 Loss from operations (3) (2,581,606 ) (269,665 ) (3,050,613 ) (5,901,884 ) Other income (4) — — (84,819 ) (84,819 ) Net loss (2,581,606 ) (269,665 ) (3,135,432 ) (5,986,703 ) Total assets, net of depreciation and amortization: United States $ 50,000 $ — $ 2,043,815 $ 2,093,815 International 384,294 — 25,596 409,890 Capital expenditures 40,221 — 8,436 48,657 Six Months Ended June 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 35,549 $ — $ — $ 35,549 Grant and other revenue 349,234 — — 349,234 Total revenue 384,783 — — 384,783 Research and development expenses 2,452,513 268,297 — 2,720,810 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 2,879 3,622,870 3,625,749 Depreciation and amortization (2) 12,081 — 25,525 37,606 Loss from operations (3) (2,079,811 ) (271,176 ) (3,648,395 ) (5,999,382 ) Other income (4) — — 358,450 358,450 Net loss (2,079,811 ) (271,176 ) (3,289,945 ) (5,640,932 ) Total assets, net of depreciation and amortization: United States $ 269,464 $ — $ 10,811,515 $ 11,080,979 International 199,741 — 590 200,331 Capital expenditures — — 2,707 2,707 ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 Depreciation and amortization are reflected in selling, general and administrative expenses ($21,771 and $19,858 for the three June 30, 2022 2021, six June 30, 2022 2021, ( 3 Loss from operations does not ( 4 Amounts consist primarily of interest income and interest expense, which are not

Note 15 - Supplemental Disclosu

Note 15 - Supplemental Disclosure for Statements of Cash Flows	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	15. Supplemental Disclosure for Statements of Cash Flows During the six June 30, 2022 2021, six June 30, 2021, 10 December 31, 2020 December 31, 2020. six June 30, 2022 2021, 401 six June 30, 2022, 2021

Note 16 - Subsequent Events

Note 16 - Subsequent Events	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	16. Subsequent Events The Company has evaluated events and transactions subsequent to June 30, 2022 10 Bridge Note On July 1, 2022, Rights Offering On August 4, 2022, August 3, 2022. August 17, 2022, one one may 3 Research and Development Expense Reimbursement The Company has previously entered into an agreement with a strategic partner for assistance with the development and supply of the active pharmaceutical ingredient (“API”) used to manufacture Lymphoseek (technetium Tc 99m two August 11, 2022, first not March 31, 2023. July 1, 2023

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	a. Basis of Presentation: June 30, 2022 three six June 30, 2022 2021 June 30, 2022 not December 31, 2021, 10 March 28, 2022 ( “2021 10 Our condensed consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Europe Limited (“Navidea Europe”) and Navidea Biopharmaceuticals Limited (“Navidea UK”), as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation.
Revenue [Policy Text Block]	b. Revenue Recognition: one We also earn revenue from product sales to end customers, primarily in Europe. Revenue from product sales is generally recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Our customers have no may In addition, we earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development (“R&D”) costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3.
Research and Development Expense, Policy [Policy Text Block]	c Research and Development Costs: d. Inventory: first first 6. e. Intangible Assets: no six June 30, 2022 2021, six June 30, 2022 2021, f. Leases: 2018. 12 not 9. g. Contingent Liabilities: 450, Contingencies 10 10. h. Recently Adopted Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 2021 04 2021 04 December 15, 2021, 2021 04 not In November 2021, No. 2021 10, Disclosures by Business Entities about Government Assistance 2021 10 2021 10 1 2 3 2021 10 December 15, 2021. 2021 10 1 2 2021 10 not

Note 3 - Revenue From Contrac_2

Note 3 - Revenue From Contracts With Customers (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Sales revenue: Tc99m tilmanocept - Europe $ 6,519 $ — $ 6,519 $ — License revenue: Tc99m tilmanocept - Europe $ — $ 13,063 $ — $ 35,549
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Total deferred revenue, beginning of period $ 800,000 $ 700,000 $ 700,000 $ 700,000 Deferred revenue related to milestones achieved — — 100,000 — Deferred revenue related to milestones achieved, written off due to contract renegotiations (100,000 ) — (100,000 ) — Total deferred revenue, end of period $ 700,000 $ 700,000 $ 700,000 $ 700,000

Note 4 - Stock-based Compensa_2

Note 4 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Six Months Ended June 30, 2022 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding, January 1, 2022 919,790 $ 5.67 6.5 $ — Granted 12,500 0.83 Cancelled/Forfeited (152,455 ) 2.38 Expired (53,755 ) 29.32 Outstanding, June 30, 2022 726,080 $ 4.52 6.0 $ — Exercisable, June 30, 2022 545,665 $ 5.52 4.9 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Six Months Ended June 30, 2022 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2022 95,000 $ 1.40 Vested (5,000 ) 1.96 Unvested, June 30, 2022 90,000 $ 1.37

Note 6 - Inventory (Tables)

Note 6 - Inventory (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2022 December 31, Materials $ 193,806 $ 50,000 Finished goods 123,066 101,155 Reserve for obsolete finished goods (1,202 ) — Total inventory, net $ 315,670 $ 151,155

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity of Lease Liabilities Operating Lease 2022 (remaining) $ 103,332 2023 19,699 2024 1,355 Total undiscounted operating lease payments 124,386 Less imputed interest 3,915 Present value of operating lease liabilities $ 120,471
Lessee, Operating Lease, Assets and Liabilities [Table Text Block]	Balance Sheet Classification Current lease liabilities $ 118,409 Noncurrent lease liabilities 2,062 Total operating lease liabilities $ 120,471
Lessee, Leases, Other Information [Table Text Block]	Other Information Weighted-average remaining lease term for operating leases (in years) 0.6 Weighted-average discount rate for operating leases 10.9 %

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended June 30, 2022 Diagnostics Therapeutics Corporate Total Sales revenue: United States $ — $ — $ — $ — International 6,519 — — 6,519 Grant and other revenue 51,007 — — 51,007 Total revenue 57,526 — — 57,526 Cost of revenue, excluding depreciation and amortization 473 — — 473 Research and development expenses 1,636,691 87,297 — 1,723,988 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,001 1,230,894 1,233,895 Depreciation and amortization (2) 6,041 — 15,730 21,771 Loss from operations (3) (1,585,679 ) (90,298 ) (1,246,624 ) (2,922,601 ) Other expense (4) — — (76,858 ) (76,858 ) Net loss (1,585,679 ) (90,298 ) (1,323,482 ) (2,999,459 ) Total assets, net of depreciation and amortization: United States $ 50,000 $ — $ 2,043,815 $ 2,093,815 International 384,294 — 25,596 409,890 Capital expenditures 40,221 — 8,436 48,657 Three Months Ended June 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 13,063 $ — $ — $ 13,063 Grant and other revenue 247,983 — — 247,983 Total revenue 261,046 — — 261,046 Research and development expenses 1,358,123 139,933 — 1,498,056 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 873 1,411,879 1,412,752 Depreciation and amortization (2) 6,041 — 13,817 19,858 Loss from operations (3) (1,103,118 ) (140,806 ) (1,425,696 ) (2,669,620 ) Other expense (4) — — (4,420 ) (4,420 ) Net loss (1,103,118 ) (140,806 ) (1,430,116 ) (2,674,040 ) Total assets, net of depreciation and amortization: United States $ 269,464 $ — $ 10,811,515 $ 11,080,979 International 199,741 — 590 200,331 Capital expenditures — — 2,707 2,707 Six Months Ended June 30, 2022 Diagnostics Therapeutics Corporate Total Sales revenue: United States $ — $ — $ — $ — International 6,519 — — 6,519 Grant and other revenue 51,007 — — 51,007 Total revenue 57,526 — — 57,526 Cost of revenue, excluding depreciation and amortization 473 — — 473 Research and development expenses 2,626,578 266,664 — 2,893,242 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,001 3,018,045 3,021,046 Depreciation and amortization (2) 12,081 — 32,568 44,649 Loss from operations (3) (2,581,606 ) (269,665 ) (3,050,613 ) (5,901,884 ) Other income (4) — — (84,819 ) (84,819 ) Net loss (2,581,606 ) (269,665 ) (3,135,432 ) (5,986,703 ) Total assets, net of depreciation and amortization: United States $ 50,000 $ — $ 2,043,815 $ 2,093,815 International 384,294 — 25,596 409,890 Capital expenditures 40,221 — 8,436 48,657 Six Months Ended June 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 35,549 $ — $ — $ 35,549 Grant and other revenue 349,234 — — 349,234 Total revenue 384,783 — — 384,783 Research and development expenses 2,452,513 268,297 — 2,720,810 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 2,879 3,622,870 3,625,749 Depreciation and amortization (2) 12,081 — 25,525 37,606 Loss from operations (3) (2,079,811 ) (271,176 ) (3,648,395 ) (5,999,382 ) Other income (4) — — 358,450 358,450 Net loss (2,079,811 ) (271,176 ) (3,289,945 ) (5,640,932 ) Total assets, net of depreciation and amortization: United States $ 269,464 $ — $ 10,811,515 $ 11,080,979 International 199,741 — 590 200,331 Capital expenditures — — 2,707 2,707

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Patent and Trademark Costs		$ 190,727	$ 104,067
Previously Capitalized Patent Costs Abandoned	$ 0	$ 62,388
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		5 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		15 years

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Aug. 03, 2022	Jul. 01, 2022	Apr. 12, 2022	Apr. 10, 2022
Subsequent Event [Member]
Rights Offering, Shares Authorized (in shares)	35,000
Shares Issued, Price Per Share (in dollars per share)	$ 1,000
Proceeds from Issuance or Sale of Equity, Total	$ 35
Subsequent Event [Member] | Series I Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)	1,538
Proceeds from Issuance or Sale of Equity, Total	$ 35
Purchase Agreement [Member] | Vice Chairman of Board of Directors [Member]
Debt Instrument, Face Amount				$ 2.5
Proceeds from Issuance of Long-Term Debt, Total			$ 1.5
Debt Instrument, Interest Rate, Stated Percentage				8%
Purchase Agreement [Member] | Vice Chairman of Board of Directors [Member] | Subsequent Event [Member]
Proceeds from Issuance of Long-Term Debt, Total		$ 1

Note 3 - Revenue From Contrac_3

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Contract with Customer, Payment Term, Minimum (Day)			15 days
Contract with Customer, Payment Term, Maximum (Day)			90 days
Contract with Customer, Transaction Price of Royalties Using Expected Value Method	$ 0		$ 0
Revenue from Contract with Customer, Including Assessed Tax	6,519	$ 13,063	6,519	$ 35,549
Contract with Customer, Asset, Impairment Loss	0	0	0	0
Sales Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax	6,519	0	6,519	0
Contract with Customer, Asset, after Allowance for Credit Loss, Total	3,903		3,903		$ 0
License [Member]
Revenue from Contract with Customer, Including Assessed Tax	0	13,063	0	35,549
Contract with Customer, Asset, after Allowance for Credit Loss, Total	0		0		$ 1,021
Grant [Member]
Revenue Not from Contract with Customer	$ 51,007	$ 72,983	$ 51,007	$ 74,233
INDIA
Contract with Customer, Term of Contract (Year)			8 years
CHINA
Contract with Customer, Term of Contract (Year)			10 years

Note 3 - Revenue From Contrac_4

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Sales revenue	$ 6,519	$ 13,063	$ 6,519	$ 35,549
Sales Revenue [Member]
Sales revenue	6,519	0	6,519	0
License [Member]
Sales revenue	0	13,063	0	35,549
Diagnostics Segment [Member] | License [Member]
Sales revenue		13,063		35,549
Diagnostics Segment [Member] | Europe [Member] | Sales Revenue [Member]
Sales revenue	6,519	0	6,519	0
Diagnostics Segment [Member] | Europe [Member] | License [Member]
Sales revenue	$ 0	$ 13,063	$ 0	$ 35,549

Note 3 - Revenue From Contrac_5

Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Total deferred revenue, beginning of period	$ 800,000	$ 700,000	$ 700,000	$ 700,000
Deferred revenue related to milestones achieved	0	0	100,000	0
Deferred revenue related to milestones achieved, written off due to contract renegotiations	(100,000)	0	(100,000)	0
Total deferred revenue, end of period	$ 700,000	$ 700,000	$ 700,000	$ 700,000

Note 4 - Stock-based Compensa_3

Note 4 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement, Expense	$ 40,555	$ 142,180	$ 225,405	$ 263,478
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 0.65
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum			93.94%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			2.34%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)			6 years 3 months
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 136,148		$ 136,148
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 7 months 6 days

Note 4 - Stock-based Compensa_4

Note 4 - Stock-based Compensation - Summary of Stock Option Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Outstanding at beginning of period (in shares)	919,790
Outstanding at beginning of period, weighted average exercise price (in dollars per share)	$ 5.67
Outstanding, weighted average remaining contractual life (Year)	6 years	6 years 6 months
Granted (in shares)	12,500
Granted, weighted average exercise price (in dollars per share)	$ 0.83
Cancelled/Forfeited (in shares)	(152,455)
Cancelled/Forfeited, weighted average exercise price (in dollars per share)	$ 2.38
Expired (in shares)	(53,755)
Expired, weighted average exercise price (in dollars per share)	$ 29.32
Outstanding at end of period (in shares)	726,080	919,790
Outstanding at end of period, weighted average exercise price (in dollars per share)	$ 4.52	$ 5.67
Exercisable at end of period (in shares)	545,665
Exercisable at end of period, weighted average exercise price (in dollars per share)	$ 5.52
Exercisable, weighted average remaining contractual life (Year)	4 years 10 months 24 days

Note 4 - Stock-based Compensa_5

Note 4 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Unvested at beginning of period (in shares) | shares	95,000
Unvested at beginning of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.40
Vested (in shares) | shares	(5,000)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.96
Unvested at end of period (in shares) | shares	90,000
Unvested at end of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.37

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Stock Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,148,404	1,684,694
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	90,000	60,000

Note 6 - Inventory (Details Tex

Note 6 - Inventory (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Finished Goods [Member]
Inventory, Allocated to Research and Development Expense	$ 1,000	$ 5,000

Note 6 - Inventory - Net Invent

Note 6 - Inventory - Net Inventory (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Materials	$ 193,806	$ 50,000
Finished goods	123,066	101,155
Reserve for obsolete finished goods	(1,202)	0
Total inventory, net	$ 315,670	$ 151,155

Note 7 - Accounts Payable, Ac_2

Note 7 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - Director Fees [Member] - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Account Payable [Member]
Due to Related Parties, Current, Total	$ 172,932	$ 57,099
Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 1,061,163	$ 1,194,719

Note 8 - Notes Payable (Details

Note 8 - Notes Payable (Details Textual) - USD ($)				1 Months Ended		3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jun. 30, 2022	Apr. 10, 2022	Nov. 30, 2021	Nov. 30, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Difference Betweent Value of Conversion Stocks			$ 821,250
Interest Expense, Debt, Total						$ 83,596	$ 1,113	$ 87,308	$ 3,883
Notes Payable, Current, Total		$ 0				0		0		$ 453,427
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | FIF [Member]
Debt Instrument, Face Amount				$ 565,760	$ 442,041
Debt Instrument, Interest Rate, Stated Percentage				4.36%	3.50%
Debt Instrument, Term (Year)				5 months	7 months
Interest Expense, Debt, Total						414	1,113	4,126	3,883
Debt Instrument, Periodic Payment, Total				$ 114,388	$ 63,888
Notes Payable, Current, Total							$ 0		$ 0
Series E Preferred Stock Exchanged for Sereis F and G Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)			50,000
Series E Preferred Stock Exchanged for Sereis F Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares)			1,740
Series E Preferred Stock Exchanged for Sereis G Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares)			3,260
Bridge Loan [Member]
Debt Instrument, Face Amount			$ 2,500,000
Proceeds from Issuance of Long-Term Debt, Total			$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage			8%
Debt Instrument, Term (Year)			2 years
Debt Instrument, Unamortized Discount, Total		779,695	$ 835,876			779,695		779,695
Debt Issuance Costs, Net, Total			$ 14,626
Interest Expense, Debt, Total		83,182
Long-Term Debt, Total		$ 1,500,000				$ 1,500,000		$ 1,500,000
Bridge Loan [Member] | Subsequent Event [Member]
Proceeds from Issuance of Long-Term Debt, Total	$ 1,000,000
Long-Term Debt, Total	$ 2,500,000

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual)	1 Months Ended	3 Months Ended			6 Months Ended
	Jun. 30, 2017 USD ($)	Jun. 30, 2022 USD ($) ft²	Mar. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) ft²	Jun. 30, 2021 USD ($)	Sep. 30, 2021 ft²
Operating Lease, Expense		$ 35,497		$ 43,913	$ 73,173	$ 89,745
Operating Lease, Payments					$ 187,779	$ 185,421
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²							5,000
Operating Lease, Monthly Base Rent			$ 3,012
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²		25,000			25,000
Operating Lease, Monthly Base Rent	$ 39,124				$ 28,149
Lessee, Operating Lease, Renewal Term (Year)		5 years			5 years
Office Equipment [Member]
Operating Lease, Monthly Base Rent					$ 136
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent					$ 287

Note 9 - Leases - Maturity of L

Note 9 - Leases - Maturity of Lease Liabilities (Details)	Jun. 30, 2022 USD ($)
2022 (remaining)	$ 103,332
2023	19,699
2024	1,355
Total undiscounted operating lease payments	124,386
Less imputed interest	3,915
Present value of operating lease liabilities	$ 120,471

Note 9 - Leases - Balance Sheet

Note 9 - Leases - Balance Sheet Classification (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current lease liabilities	$ 118,409	$ 275,718
Noncurrent lease liabilities	2,062	$ 20,288
Present value of operating lease liabilities	120,471
Other Current Liabilities [Member]
Current lease liabilities	118,409
Other Noncurrent Liabilities [Member]
Noncurrent lease liabilities	$ 2,062

Note 9 - Leases - Other Informa

Note 9 - Leases - Other Information (Details)	Jun. 30, 2022
Weighted-average remaining lease term for operating leases (in years) (Year)	7 months 6 days
Weighted-average discount rate for operating leases	10.90%

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual) - USD ($)

1 Months Ended

3 Months Ended

19 Months Ended

Dec. 09, 2021

Nov. 21, 2021

May 27, 2021

Mar. 16, 2021

Nov. 27, 2019

Aug. 14, 2018

Apr. 09, 2018

Nov. 02, 2017

Nov. 30, 2018

Jun. 30, 2022

Jun. 30, 2021

Mar. 31, 2022

Jan. 31, 2022

Dec. 31, 2021

Mar. 31, 2021

Dec. 31, 2020

Aug. 31, 2018

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ (4,240,647)

$ 6,436,170

$ (2,109,442)

$ 624,743

$ 5,008,882

$ 2,046,907

Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares)

7,500

0

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ 221,361

$ 221,142

221,354

$ 221,277

$ 219,703

$ 218,146

MT [Member]

Ownership Percentage

60%

Former Chief Executive Officer and President [Member]

Common Stock Shares Provided by Agreement (in shares)

1,175,000

Common Stock Shares Provided by Agreement, Escrow Period (Month)

18 months

Former Chief Executive Officer and President [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares)

925,000

Stock Issued During Period, Shares, New Issues Placed in Escrow (in shares)

250,000

Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member]

Ownership Percentage

5%

CRG Loan Agreement, Texas Case [Member]

Litigation Settlement, Attorneys’ Fees

$ 2,800,000

CRG Loan Agreement, Texas Case [Member] | CRG [Member] | Term Loan Agreement [Member]

Overpayment of Debt

$ 4,200,000

Ohio Court of Common Pleas [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 4,300,000

Litigation Settlement, Reversal of Amount Awarded from Other Party

$ 4,300,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

New York Litigation Involving Former CEO and President [Member] | Judicial Ruling [Member]

Litigation Settlement, Amount Can Be Awarded to Other Party for Indemnification for Attorneys’ Fees

$ 14,955

Litigation Settlement, Amount Can Be Advanced to Other Party for Attorneys’ Fees Subject to Repayment

$ 1,237.50

Litigation Settlement, Advancement for Attorney's Fees and Disbursements

$ 143,172.55

Delaware Litigation Involving Former CEO and President [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 66,796.33

CRG [Member]

Draws on Letter of Credit

$ 7,153,000

Note 11 - Equity (Details Textu

Note 11 - Equity (Details Textual) - USD ($)			3 Months Ended		6 Months Ended
	Apr. 10, 2022	Apr. 07, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 31, 2022	Dec. 31, 2021
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance					$ 292,517			$ 731,299
Additional Paid in Capital, Total					$ 372,019,758			370,459,705
Operating Loss Carryforwards								164,000,000
Share Purchase Right, Ownership Percentage Threshold		4.99%
Share Purchase Right, Ownership Percentage Trigger		0.50%
Share Purchase Right, Discount Percentage		50%
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)					53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan			$ 44,720	$ 76,846	$ 44,720	$ 76,846
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution					$ 44,720	$ 76,846
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)			53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan			$ 53	$ 30
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)			16,632
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)					16,632
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution					$ 16,965
Series E Preferred Stock Exchanged for Sereis F and G Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)	50,000
Series E Preferred Stock Exchanged for Sereis F Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares)	1,740
Series E Preferred Stock Exchanged for Sereis G Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares)	3,260
Bridge Loan [Member]
Debt Instrument, Face Amount	$ 2,500,000
Proceeds from Issuance of Long-Term Debt, Total	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage	8%
Debt Instrument, Term (Year)	2 years
MT [Member]
Ownership Percentage							60%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance								$ 731,299
MT Preferred Stock [Member]
Preferred Stock, Stock Returned (in shares)							6
Additional Paid in Capital, Total							$ 438,778
Series H Preferred Stock [Member]
Share Purchase Right, Shares Issuable Per Each Right (in shares)		1,000

Note 12 - Stock Warrants (Detai

Note 12 - Stock Warrants (Details Textual) - $ / shares	Mar. 03, 2022	Jun. 30, 2022
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.30
Class of Warrant or Right, Outstanding (in shares)		422,324
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.20
Warrants and Rights Outstanding, Term (Year)		1 year
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 49.80
Warrants and Rights Outstanding, Term (Year)		13 years 1 month 6 days
Series NN Warrants [Member]
Class of Warrant or Right, Expired in Period (in shares)	550,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 30

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Unrecognized Tax Benefits, Ending Balance	$ 0	$ 0
Operating Loss Carryforwards		$ 164,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	164,100
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	9,100
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 20,100

Note 14 - Segments (Details Tex

Note 14 - Segments (Details Textual)		3 Months Ended		6 Months Ended
		Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Revenues, Total		$ 57,526	$ 261,046	$ 57,526	$ 384,783
Number of Primary Types of Products Sold		2		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 21,771	$ 19,858	$ 44,649	$ 37,606
Intersegment Eliminations [Member]
Revenues, Total				$ 0
[1]Depreciation and amortization are reflected in selling, general and administrative expenses ($21,771 and $19,858 for the three-month periods ended June 30, 2022 and 2021, and $44,649 and $37,606 for the six-month periods ended June 30, 2022 and 2021, respectively).

Note 14 - Segments - Segment In

Note 14 - Segments - Segment Information (Details) - USD ($)		3 Months Ended						6 Months Ended
		Jun. 30, 2022		Mar. 31, 2022	Jun. 30, 2021		Mar. 31, 2021	Jun. 30, 2022		Jun. 30, 2021		Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax		$ 6,519			$ 13,063			$ 6,519		$ 35,549
Grant and other revenue		51,007			247,983			51,007		349,234
Revenues, Total		57,526			261,046			57,526		384,783
Cost of revenue, excluding depreciation and amortization		473			0			473		0
Research and development expenses		1,723,988			1,498,056			2,893,242		2,720,810
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,233,895			1,412,752			3,021,046		3,625,749
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	21,771			19,858			44,649		37,606
Loss from operations	[3]	(2,922,601)			(2,669,620)			(5,901,884)		(5,999,382)
Other expense (4)		(76,858)	[4]		(4,420)	[4]		(84,819)	[4]	358,450	[5]
Net loss		(2,999,459)		$ (2,987,245)	(2,674,040)		$ (2,966,892)	(5,986,703)		(5,640,932)
Total assets, net of depreciation and amortization		2,503,705						2,503,705				$ 6,644,833
Capital expenditures		48,657			2,707			48,657		2,707
UNITED STATES
Total assets, net of depreciation and amortization		2,093,815			11,080,979			2,093,815		11,080,979
Non-US [Member]
Total assets, net of depreciation and amortization		409,890			200,331			409,890		200,331
Diagnostics Segment [Member]
Grant and other revenue		51,007			247,983			51,007		349,234
Revenues, Total		57,526			261,046			57,526		384,783
Cost of revenue, excluding depreciation and amortization		473						473
Research and development expenses		1,636,691			1,358,123			2,626,578		2,452,513
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	0			0			0		0
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	6,041			6,041			12,081		12,081
Loss from operations	[3]	(1,585,679)			(1,103,118)			(2,581,606)		(2,079,811)
Other expense (4)		0	[4]		0	[4]		0	[4]	0	[5]
Net loss		(1,585,679)			(1,103,118)			(2,581,606)		(2,079,811)
Capital expenditures		40,221			0			40,221		0
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		50,000			269,464			50,000		269,464
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		384,294			199,741			384,294		199,741
Therapeutics Segment [Member]
Grant and other revenue		0			0			0		0
Revenues, Total		0			0			0		0
Cost of revenue, excluding depreciation and amortization		0						0
Research and development expenses		87,297			139,933			266,664		268,297
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	3,001			873			3,001		2,879
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	0			0			0		0
Loss from operations	[3]	(90,298)			(140,806)			(269,665)		(271,176)
Other expense (4)		0	[4]		0	[4]		0	[4]	0	[5]
Net loss		(90,298)			(140,806)			(269,665)		(271,176)
Capital expenditures		0			0			0		0
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		0			0			0		0
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		0			0			0		0
Corporate Segment [Member]
Grant and other revenue		0			0			0		0
Revenues, Total		0			0			0		0
Cost of revenue, excluding depreciation and amortization		0						0
Research and development expenses		0			0			0		0
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,230,894			1,411,879			3,018,045		3,622,870
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	15,730			13,817			32,568		25,525
Loss from operations	[3]	(1,246,624)			(1,425,696)			(3,050,613)		(3,648,395)
Other expense (4)		(76,858)	[4]		(4,420)	[4]		(84,819)	[4]	358,450	[5]
Net loss		(1,323,482)			(1,430,116)			(3,135,432)		(3,289,945)
Capital expenditures		8,436			2,707			8,436		2,707
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		2,043,815			10,811,515			2,043,815		10,811,515
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		25,596			590			25,596		590
License [Member]
Revenue from Contract with Customer, Including Assessed Tax		0			13,063			0		35,549
License [Member] | Diagnostics Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax					13,063					35,549
License [Member] | Therapeutics Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax					0					0
License [Member] | Corporate Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax					0					0
Sales Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax		6,519			$ 0			6,519		$ 0
Sales Revenue [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0						0
Sales Revenue [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		6,519						6,519
Sales Revenue [Member] | Diagnostics Segment [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0						0
Sales Revenue [Member] | Diagnostics Segment [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		6,519						6,519
Sales Revenue [Member] | Therapeutics Segment [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0						0
Sales Revenue [Member] | Therapeutics Segment [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		0						0
Sales Revenue [Member] | Corporate Segment [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0						0
Sales Revenue [Member] | Corporate Segment [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 0						$ 0
[1]General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.[2]Depreciation and amortization are reflected in selling, general and administrative expenses ($21,771 and $19,858 for the three-month periods ended June 30, 2022 and 2021, and $44,649 and $37,606 for the six-month periods ended June 30, 2022 and 2021, respectively).[3]Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.[4]Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.[5]Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 15 - Supplemental Disclo_2

Note 15 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Interest Paid, Excluding Capitalized Interest, Operating Activities			$ 31,126	$ 4,013
Proceeds from Issuance of Preferred Stock and Preference Stock			$ 0	$ 10,475,000
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)			53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan	$ 44,720	$ 76,846	$ 44,720	$ 76,846
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution			$ 44,720	76,846
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)	53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan	$ 53	$ 30
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)	16,632
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)			16,632
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution			$ 16,965
Series D Preferred Stock [Member] | Keystone Capital Partners, LLC [Member]
Proceeds from Issuance of Preferred Stock and Preference Stock				$ 2,925,000

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($)	Aug. 11, 2022	Aug. 03, 2022	Jul. 01, 2022	Apr. 10, 2022	Jun. 30, 2022
Subsequent Event [Member]
Shares Issued, Price Per Share (in dollars per share)		$ 1,000
Proceeds from Issuance or Sale of Equity, Total		$ 35,000,000
API Agreement, Reimbursement Payments	$ 1,850,000
API Agreement, Accelerated Reimbursement Payments	$ 800,000
Subsequent Event [Member] | Series I Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)		1,538
Proceeds from Issuance or Sale of Equity, Total		$ 35,000,000
Bridge Loan [Member]
Proceeds from Issuance of Long-Term Debt, Total				$ 1,500,000
Long-Term Debt, Total					$ 1,500,000
Bridge Loan [Member] | Subsequent Event [Member]
Proceeds from Issuance of Long-Term Debt, Total			$ 1,000,000
Long-Term Debt, Total			$ 2,500,000